Leaflet DOXORUBICINA ACCORD 2mg / ml concentrate for solution for infusion

Indicated for: cancer

Route of administration: infusion

Substance: doxorubicin (antineoplastic agent)

ATC: L01DB01 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)

Precautions:
Fertility warning
Fertility warning

This medicine may affect fertility.

Dose adjustment in hepatic impairment
Dose adjustment in hepatic impairment

Dose adjustment may be needed in liver disease.

Cytotoxic / special handling
Cytotoxic / special handling

Handle with special care.

Contraception required
Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding
Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis
Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Severe skin reactions
Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Doxorubicin is a chemotherapy drug used for the treatment of various types of cancer, including breast cancer, leukemia, and lymphoma. It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division and growth.

The medication is administered intravenously, usually as part of a specific regimen, under the supervision of an oncologist. It is effective in reducing tumor size and slowing disease progression.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and, in rare cases, cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Doxorubicin. This medication must be administered exclusively in controlled environments, such as hospitals.

General data about DOXORUBICINA ACCORD 2mg / ml

  • Substance: doxorubicin
  • Date of latest medicines list: 01-06-2026
  • Product code: W65789003
  • Concentration: 2mg / ml
  • Pharmaceutical form: concentrate for solution for infusion
  • Quantity: 1
  • Product type: Generic medicine
  • Price: 320.41 RON
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
  • Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
  • Number: 10647/2018/05
  • Shelf life: 18 months-after packing for marketing;after the first opening of the bottle-it is used immediately

Concentrations available for doxorubicin

  • 10mg
  • 2mg/ml
  • 50mg

Compensation lists for DOXORUBICINA ACCORD 2mg / ml Accord

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

320.41 RON

320.41 RON

0.00 RON